GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytoMed Therapeutics Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$0.85−0.03 (-3.17%)
Close on Oct 19, 2026
CytoMed Therapeutics statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available
Income (trailing twelve months)
| Revenue | 324.39K SGD |
|---|---|
| Pretax Income | -4.00M SGD |
| Net Income | -3.98M SGD |
| EBITDA | -3.60M SGD |
| EPS (Diluted) | -0.34 SGD |
Margins
| Pretax Margin | -1232.0% |
|---|---|
| Profit Margin | -1227.1% |
| EBITDA Margin | -1111.1% |
| FCF Margin | -1336.5% |
Returns
| Return on Equity (ROE) | -51.3% |
|---|---|
| Return on Assets (ROA) | -44.1% |
Growth
| Revenue Growth (YoY) | 366.7% |
|---|
Balance sheet
| Cash & Short-Term Investments | 2.10M SGD |
|---|---|
| Total Debt | 409.50K SGD |
| Net Cash (Debt) | 1.69M SGD |
| Net Cash Per Share | 0.14 SGD |
| Equity (Book Value) | 6.54M SGD |
| Book Value Per Share | 0.55 SGD |
| Tangible Book Value | 6.42M SGD |
| Working Capital | 2.95M SGD |
Financial position
| Current Ratio | 5.17 |
|---|---|
| Quick Ratio | 5.17 |
| Debt / Equity | 0.06 |
Cash flow (trailing twelve months)
| Operating Cash Flow | -3.70M SGD |
|---|---|
| Capital Expenditures | -637.85K SGD |
| Free Cash Flow | -4.34M SGD |
| FCF Per Share | -0.37 SGD |
Efficiency
| Asset Turnover | 0.04 |
|---|
Shares
| Shares Outstanding | 11,828,400 |
|---|---|
| Shares Change (YoY) | 0.93% |
| Float | 7,458,480 |
| Shares Held by Insiders | 36.9% |
Scores
| Piotroski F-Score | 1 |
|---|
Calculated by StockData from CytoMed Therapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.